Home / Health / Rethink 'Cancer' for Low-Risk Prostate Tumors
Rethink 'Cancer' for Low-Risk Prostate Tumors
6 Jul
Summary
- Low-risk prostate cancer (GG1) may be better labeled precancerous.
- Relabeling could prevent six times more prostate cancer deaths annually.
- Fear of diagnosis leads many to unnecessary, harmful treatments.
The way low-risk prostate cancer is described may be causing undue harm, according to new research published recently in JAMA Oncology. For Grade Group 1 (GG1) prostate cancers, which are typically slow-growing and rarely life-threatening, a label of 'cancer' often induces significant stress and anxiety in patients.
Researchers propose that relabeling GG1 tumors as a precancerous condition or a prostate condition, rather than cancer, could lead to a sixfold increase in prevented prostate cancer deaths annually. This change in terminology aims to provide patients with information that more accurately reflects their disease's actual risk.
Currently, guidelines recommend a 'watch and wait' approach for GG1 cases. However, up to 40% of diagnosed men opt for surgery or radiation due to anxiety, often enduring unnecessary side effects like incontinence or impotence. Relabeling could encourage more men to undergo screening while mitigating fears of overtreatment for non-threatening tumors.
This renaming approach is not unprecedented in medicine. Similar reclassifications have occurred for other cancers, such as bladder, cervical, and thyroid cancers, where conditions once termed cancer were redefined to better reflect their low harm potential. Applying this to low-risk prostate tumors could help patients avoid needless treatments and improve screening for more aggressive forms.
